NLS Pharmaceutics Ltd. - Common Shares (NLSP)
NLSP moved a median of -1.61% 30 minutes after news, and -1.23% by the close. How NLSP actually reacts to news — the realized, point-in-time move the market made, measured across 241 labeled events over the last three years with zero look-ahead.
NLSP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 35% | 214 |
| 30-min | -1.61% | 30% | 225 |
| 60-min | -1.60% | 38% | 226 |
| to close | -1.23% | 42% | 226 |
| Middle 50% of NLSP reactions | -4.83% to +1.07% |
|---|---|
| Median reaction (30-min) | -1.61% |
| Measured reactions | 241 |
Half of all NLS Pharmaceutics Ltd. - Common Shares news events land between -4.83% and +1.07% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when NLSP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NLSP's baseline. Nothing else.
Recent NLSP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form EFFECT NewcelX Ltd. | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 6-K NewcelX Ltd. For: Nov 17 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| Form 6-K NewcelX Ltd. For: Nov 07 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| Form POS AM NewcelX Ltd. | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form 6-K NewcelX Ltd. For: Nov 04 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| Form 6-K NewcelX Ltd. For: Nov 03 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| Form 6-K NLS Pharmaceutics Ltd. For: Oct 30 | SEC filing · Form 6-K | SEC EDGAR | +1.94% | -1.05% | |
| NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs | Press release | PR Newswire | +1.94% | -1.05% | |
| NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger | Press release | PR Newswire | — | — | |
| Form 6-K NLS Pharmaceutics Ltd. For: Oct 29 | SEC filing · Form 6-K | SEC EDGAR | -7.29% | -22.04% | |
| NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares | Press release | PR Newswire | -7.29% | -22.04% | |
| NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger | Press release | PR Newswire | -7.29% | -22.04% | |
| NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem | Press release | PR Newswire | -7.29% | -22.04% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Oct 28 | SEC filing · Form 6-K | SEC EDGAR | -7.29% | -22.04% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Oct 27 | SEC filing · Form 6-K | SEC EDGAR | +0.44% | -1.59% | |
| NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies | Press release | PR Newswire | +0.44% | -1.59% | |
| Form POS AM NLS Pharmaceutics Ltd. | SEC filing · Form POS | SEC EDGAR | +0.44% | -1.59% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Oct 23 | SEC filing · Form 6-K | SEC EDGAR | -1.45% | -4.35% | |
| NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 | Press release | PR Newswire | -1.45% | -4.35% | |
| Form POS AM NLS Pharmaceutics Ltd. | SEC filing · Form POS | SEC EDGAR | +0.00% | -0.59% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Oct 09 | SEC filing · Form 6-K | SEC EDGAR | -0.27% | -4.35% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -1.60% | -2.04% | |
| Form EFFECT NLS Pharmaceutics Ltd. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +15.64% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Sep 30 | SEC filing · Form 6-K | SEC EDGAR | -6.69% | -18.30% | |
| NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting | Press release | PR Newswire | -6.69% | -18.30% | |
| Form F-1 NLS Pharmaceutics Ltd. | SEC filing · Form F-1 | SEC EDGAR | -0.71% | -2.67% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Sep 19 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +7.28% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Sep 10 | SEC filing · Form 6-K | SEC EDGAR | +2.00% | +3.50% | |
| Form EFFECT NLS Pharmaceutics Ltd. | SEC filing · Form EFFECT | SEC EDGAR | +2.00% | +3.50% | |
| Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger | Press release | PR Newswire | +2.00% | +3.50% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Sep 04 | SEC filing · Form 6-K | SEC EDGAR | -2.03% | +1.01% | |
| NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients | Press release | PR Newswire | -2.03% | +1.01% | |
| Form F-4/A NLS Pharmaceutics Ltd. | SEC filing · Form F-4 | SEC EDGAR | -2.03% | +1.01% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Aug 29 | SEC filing · Form 6-K | SEC EDGAR | +0.95% | -1.91% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Aug 25 | SEC filing · Form 6-K | SEC EDGAR | -0.89% | -4.46% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Aug 06 | SEC filing · Form 6-K | SEC EDGAR | -0.13% | -0.53% | |
| Form F-4/A NLS Pharmaceutics Ltd. | SEC filing · Form F-4 | SEC EDGAR | +0.52% | +4.14% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Jul 18 | SEC filing · Form 6-K | SEC EDGAR | +0.45% | -0.45% | |
| Form F-4/A NLS Pharmaceutics Ltd. | SEC filing · Form F-4 | SEC EDGAR | +0.45% | -0.45% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Jul 17 | SEC filing · Form 6-K | SEC EDGAR | +0.24% | +0.90% | |
| NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy | Press release | PR Newswire | +0.24% | +0.90% | |
| Form D NLS Pharmaceutics Ltd. | SEC filing · Form D | SEC EDGAR | +0.91% | -4.54% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Jul 01 | SEC filing · Form 6-K | SEC EDGAR | -1.70% | +9.83% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -2.46% | +2.11% | |
| NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing | Press release | PR Newswire | -2.46% | +2.11% | |
| Form F-4/A NLS Pharmaceutics Ltd. | SEC filing · Form F-4 | SEC EDGAR | -0.22% | -2.15% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Jun 16 | SEC filing · Form 6-K | SEC EDGAR | +0.87% | -1.73% | |
| NLS Pharmaceutics CEO Issues Letter to Shareholders | Press release | PR Newswire | +0.87% | -1.73% | |
| Form 6-K NLS Pharmaceutics Ltd. For: Jun 10 | SEC filing · Form 6-K | SEC EDGAR | -2.29% | -2.67% | |
| Form F-4/A NLS Pharmaceutics Ltd. | SEC filing · Form F-4 | SEC EDGAR | -0.95% | +4.96% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NLSP section they belong to.
Where else NLSP is measured.
NLSP earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is NLS Pharmaceutics Ltd. - Common Shares's median reaction calculated?
Every labeled NLSP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 241 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 30% of NLSP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NLSP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.